The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin
出版年份 2016 全文链接
标题
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin
作者
关键词
Apoptosis, Cancer treatment, Histones, Cell viability testing, Blood, DNA-binding proteins, Cell death, Lymphocytes
出版物
PLoS One
Volume 11, Issue 1, Pages e0146115
出版商
Public Library of Science (PLoS)
发表日期
2016-01-12
DOI
10.1371/journal.pone.0146115
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma
- (2015) Elise A. Olsen DERMATOLOGIC CLINICS
- Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA
- (2014) Ulrike Heinicke et al. CANCER LETTERS
- Novel therapies for cutaneous T-cell lymphoma: what does the future hold?
- (2014) Emmanuella Guenova et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells
- (2014) Jane J. Sung et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
- (2014) Sarah I. Jawed et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
- (2014) Prithviraj Bose et al. PHARMACOLOGY & THERAPEUTICS
- The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells
- (2013) Kornelius Kerl et al. BMC CANCER
- A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
- (2013) M Kaliszczak et al. BRITISH JOURNAL OF CANCER
- Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma
- (2013) Shruti Bhatt et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel Therapeutic Strategies for Cutaneous T-Cell Lymphoma in Advanced Stages
- (2013) Lillian Kun et al. SEMINARS IN HEMATOLOGY
- HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
- (2013) J E Bolden et al. Cell Death & Disease
- Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions
- (2012) O.E. Akilov et al. BRITISH JOURNAL OF DERMATOLOGY
- The Fas apoptotic pathway in cutaneous T-cell lymphomas: Frequent expression of phenotypes associated with resistance to apoptosis
- (2012) Nathalie Stutz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Romidepsin and interferon gamma: A novel combination for refractory cutaneous T-cell lymphoma
- (2012) Sara Samimi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor
- (2012) Nataly Tarasenko et al. PLoS One
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- (2011) D Li et al. CELL DEATH AND DIFFERENTIATION
- Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer
- (2011) K Ted Thurn et al. Future Oncology
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity
- (2010) Nataly Tarasenko et al. INVESTIGATIONAL NEW DRUGS
- The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy
- (2010) Erik R. Sampson et al. JOURNAL OF ORTHOPAEDIC RESEARCH
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
- (2009) P. T. Bradford et al. BLOOD
- Rational Combinations Using HDAC Inhibitors
- (2009) M. Bots et al. CLINICAL CANCER RESEARCH
- Clinical Studies of Histone Deacetylase Inhibitors
- (2009) H. M. Prince et al. CLINICAL CANCER RESEARCH
- Doxorubicin: The Good, the Bad and the Ugly Effect
- (2009) Cristina Carvalho et al. CURRENT MEDICINAL CHEMISTRY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome
- (2009) Jennifer M. Gardner et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression
- (2008) E. Contassot et al. BLOOD
- Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
- (2008) Nataly Tarasenko et al. CLINICAL & EXPERIMENTAL METASTASIS
- Acetylation of non-histone proteins modulates cellular signalling at multiple levels
- (2008) Stephanie Spange et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started